Siremadlin

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameSiremadlin
Drug Alias NameHDM-201NVP-HDM201
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 inhibitors
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsUveal melanomaSolid tumoursPrimary Myelofibrosis +[14
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[25
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Active IndicationsHepatic InsufficiencyNeoplasm MetastasisHematologic Neoplasms +[6
Inactive IndicationsUveal melanomaSolid tumoursPrimary Myelofibrosis +[8

Other Information

ATC CodeN/A
Related LinksN/A